Pulmonary Vein News and Research

RSS

First cryoablation procedure using new mapping catheter performed at Baylor Heart and Vascular Hospital

Baylor Jack and Jane Hamilton Heart and Vascular Hospital today announced the first patient procedure in the U.S. using the Achieve Mapping Catheter, an intra-cardiac electrophysiology diagnostic catheter that can be used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation.

3 May 2011

FDA approves Achieve Mapping Catheter for use in first patient procedure

Medtronic, Inc. today announced the U.S. Food and Drug Administration approval for use, and the first patient procedure using the Achieve™ Mapping Catheter, an intra-cardiac electrophysiology diagnostic catheter that can be used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation.

3 May 2011

New research: 56% of Canadians with AF do not fear having fatal stroke

New research reveals more than half of Canadians living with atrial fibrillation do not fear having a stroke, despite AF-related strokes being more severe, debilitating and twice as likely to be fatal.

19 Apr 2011

Medtronic's Resolute drug-eluting stent pivotal U.S. data to be presented at ACC.11

Medtronic, Inc., today announced the imminent release of the pivotal U.S. data on its Resolute drug-eluting stent at ACC.11, the 60th Annual Scientific Session & Expo of the American College of Cardiology, which takes place April 2-5 in New Orleans.

29 Mar 2011

SLEH treats irregular heartbeat with novel minimally invasive cold cryoballoon technology

A physician affiliated with Texas Heart® Institute (THI) at St. Luke's Episcopal Hospital (SLEH) is the first in Houston and among the first in the nation to treat patients for an irregular heartbeat with a new, minimally invasive cryoballoon technology that uses cold rather than heat to interrupt faulty electrical circuits in the heart.

21 Mar 2011

Medtronic launches Achieve Mapping Catheter in Europe

Medtronic, Inc. today announced the European launch of the Achieve Mapping Catheter, an intra-cardiac electrophysiology recording catheter that can be used to assess pulmonary vein isolation when treating paroxysmal atrial fibrillation.

4 Mar 2011

CardioFocus completes $30.6M private financing

CardioFocus, Inc., developer of the Endoscopic Ablation System for the transcatheter treatment of Atrial Fibrillation, announced the completion of a $30.6M private financing.

28 Feb 2011

Endosense announces completion of enrollment in EFFICAS I clinical study

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.

16 Feb 2011

New device to treat heart hiccups

"It took off to about 160 beats per minute and then dropped to 50. It seemed confused. Then it went back to normal," recalled Tsuji, 47, an avid cyclist, of that day in 2003. "I didn't notice any symptoms at that point, so I blew it off. I figured there was something wrong with it."

3 Feb 2011

Mayo Clinic uses Arctic Front Cardiac CryoAblation Catheter system for treating AF

Mayo Clinic is the first in the U.S. to use the first minimally invasive freezing balloon technology for the treatment of atrial fibrillation approved in December by the U.S. Food and Drug Administration. The first patient received the treatment Tuesday, Jan. 4.

6 Jan 2011

$FDA approves Medtronic's Arctic Front Cardiac CryoAblation Catheter system for drug refractory PAF$

FDA approves Medtronic's Arctic Front Cardiac CryoAblation Catheter system for drug refractory PAF

Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Arctic Front® Cardiac CryoAblation Catheter system, the first and only Cryoballoon in the United States indicated for the treatment of drug refractory paroxysmal atrial fibrillation (PAF). The Cryoballoon treatment involves a minimally-invasive procedure that efficiently creates circumferential lesions around the pulmonary vein, which is the source of erratic electrical signals that cause the irregular heartbeat.

20 Dec 2010

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

Medtronic, Inc. today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency ablation technology for the treatment of atrial fibrillation. AF is the most common heart arrhythmia that affects more than 250,000 Canadians and seven million people worldwide.

26 Aug 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

Patients enrolled in CLARITY-AF study

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study, comparing the efficacy, safety and efficiency of CARTO 3 System guided radiofrequency ablation using the NAVISTAR THERMOCOOL catheter versus fluoroscopy guided radiofrequency ablation using the Pulmonary Vein Ablation catheter (Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Jul 2010

Medtronic's anatomically-designed ablation catheters reduce lab time for PVI

Data from the FAST-PVI study, supported by Medtronic, Inc., shows lab time using anatomically-designed ablation catheters are more than one-third (35 percent) faster than traditional point-by-point focal ablation procedures in achieving pulmonary vein isolation (PVI). PVI is the cornerstone catheter procedure to treat paroxysmal atrial fibrillation (PAF).

19 Jun 2010

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced it has enrolled the first patients in EFFICAS I, the first study of the EFFICAS series. These patients were enrolled in Na Homolce Hospital, Prague, Czech Republic and treated by Petr Neuzil, M.D. and Vivek Reddy, M.D.

10 May 2010

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Apr 2010

St. Jude Medical to commence enrollment in IRASE AF trial

St. Jude Medical, Inc. today announced it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the IRASE AF (IRrigated Ablation System Evaluation for AF) trial, a multicenter, randomized, single-blind study evaluating the safety and efficacy of the company’s Duo 12 port open irrigated catheter ablation system for treatment of Atrial Fibrillation (AF). AF is the most common cardiac arrhythmia (abnormal heartbeat), affecting an estimated 3.3 million Americans and millions more worldwide.

4 Feb 2010

AFib: NAVISTAR THERMOCOOL Catheter provides better outcomes compared to drug therapy

According to data appearing today in JAMA, patients with a common heart rhythm disorder, called Atrial Fibrillation, who were treated with catheter ablation using the NAVISTAR® THERMOCOOL® Catheter, demonstrated significantly better outcomes at one year compared to those receiving drug therapy. In addition, the patients treated with catheter ablation reported markedly fewer symptoms and substantially improved quality of life.

27 Jan 2010

nContact Surgical initiates clinical trials of its convergent procedure for paroxysmal AF

nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, today announced the initiation of a feasibility clinical trial designed to evaluate the safety and efficacy of a combined surgical and catheter procedure, the convergent procedure, for the treatment of symptomatic paroxysmal atrial fibrillation (AF). This prospective, feasibility study will enroll patients at study sites across the United States.

2 Dec 2009